A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)

There is an ongoing burden of pneumococcal disease in children despite the use of pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite, descriptive study was designed to evaluate the safety and immunogenicity of a 3 + 1 regimen of V114 (VAXNEUVANCE™), a 15-valent P...

Celý popis

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi “Lucy” Li, Yae-Jean Kim, Yun-Kyung Kim, Jin Lee, Ji Young Park, Dong Hyun Kim, GyongSeon Yang, Hyunjung Lim, Jin Oh Kim, Robert Lupinacci, Tina M. Sterling, Marissa Wilck, Alejandra Esteves-Jaramillo, Natalie Banniettis
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2024-12-01
Edice:	Human Vaccines & Immunotherapeutics
Témata:	Vaxneuvance™ PCV15 pneumococcal conjugate vaccine infants toddlers
On-line přístup:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2321035
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)

Podobné jednotky